Products for Research Use Only

Kynurenic acid

CAT: 0804-HY-100806-01Size: 100 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-100806-01Size:100 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Kynurenic acid, an endogenous tryptophan metabolite, is a broad-spectrum antagonist targeting NMDA, glutamate, α7 nicotinic acetylcholine receptor. Kynurenic acid is also an agonist of GPR35/CXCR8.
CAS Number
492-27-3
Product Name Alternative
Quinurenic acid
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Apoptosis; CXCR; Endogenous Metabolite; GPR35 ; iGluR
Type
Natural Products
Related Pathways
Apoptosis; GPCR/G Protein; Immunology/Inflammation; Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease; Neuronal Signaling
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology; Neurological Disease; Endocrinology
Assay Protocol
https://www.medchemexpress.com/Kynurenic_acid.html
Purity
99.58
Solubility
0.1 M NaOH : 12.5 mg/mL (ultrasonic; adjust pH to 9 with NaOH) |DMSO : 9 mg/mL (ultrasonic; warming) |H2O : < 0.1 mg/mL (ultrasonic)
Smiles
O=C(C1=NC2=CC=CC=C2C(O)=C1)O
Molecular Formula
C10H7NO3
Molecular Weight
189.17
Precautions
H302, H315, H319, H335
References & Citations
[1]Wang J, et al. Kynurenic acid as a ligand for orphan G protein-coupled receptor GPR35. J Biol Chem. 2006 Aug 4;281 (31) :22021-8.|[2]Albuquerque EX, et al. Kynurenic acid as an antagonist of α7 nicotinic acetylcholine receptors in the brain: facts and challenges. Biochem Pharmacol. 2013 Apr 15;85 (8) :1027-32.|[3]Małaczewska J, et al. Effect of oral administration of kynurenic acid on the activity of the peripheral blood leukocytes in mice. Cent Eur J Immunol. 2014;39 (1) :6-13.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Natural Products
Clinical Information
No Development Reported
Isoform
Human Endogenous Metabolite; NMDA Receptor

Alternative Products

Popular Products